CCR5 targeted cell therapy for hiv and prevention of viral escape

Viruses

Volumn 7, Issue 8, 2015, Pages 4186-4203

  Hütter, Gero ^a   Bodor, Josef ^b   Ledger, Scott ^c   Boyd, Maureen ^d   Millington, Michelle ^d   Tsie, Marlene ^d   Symonds, Geoff ^d  

^a Cellex Patient Treatment GmbH   (Germany)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Calimmune Australia Inc   (United States)

Author keywords

CCR5; CCR5 delta32; Chemokine receptor; Gene therapy; HIV 1; Tropism; Viral escape

Indexed keywords

BURIXAFOR; CD27 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 DELTA 32; CHEMOKINE RECEPTOR CXCR4; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9 NUCLEASE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PLERIXAFOR; PROSTAGLANDIN E2; SHORT HAIRPIN RNA; THYMOCYTE ANTIBODY; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE; CCR5 PROTEIN, HUMAN; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CYTOPATHOGENIC EFFECT; DOWN REGULATION; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; LONG TERMINAL REPEAT; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRAL TROPISM; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; GENE SILENCING; GENETICS; HIV INFECTIONS; METABOLISM; PROCEDURES; STEM CELL TRANSPLANTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BIOLOGICAL THERAPY; GENE KNOCKDOWN TECHNIQUES; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, HIV; STEM CELL TRANSPLANTATION;

EID: 84938412709     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7082816     Document Type: Article

References (71)

1. Doms, R.W. Beyond receptor expression: The influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000, 276, 229-237. [CrossRef] [PubMed]
2. Weiss, R.A. Thirty years on: HIV receptor gymnastics and the prevention of infection. BMC Biol. 2013,11, e57. [CrossRef] [PubMed]
3. Connor, R.I.; Sheridan, K.E.; Ceradini, D.; Choe, S.; Landau, N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 1997, 185, 621-628. [CrossRef] [PubMed]
4. Scarlatti, G.; Tresoldi, E.; Bjorndal, A.; Fredriksson, R.; Colognesi, C.; Deng, H.K.; Malnati, M.S.; Plebani, A.; Siccardi, A.G.; Littman, D.R., et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 1997, 3, 1259-1265. [CrossRef] [PubMed]
5. Samson, M.; Libert, F.; Doranz, B.J.; Rucker, J.; Liesnard, C.; Farber, C.M.; Saragosti, S.; Lapoumeroulie, C.; Cognaux, J.; Forceille, C., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382, 722-725. [CrossRef] [PubMed]
6. Nazari, R.; Joshi, S. CCR5 as target for HIV-1 gene therapy. Curr. Gene Ther. 2008, 8, 264-272. [CrossRef] [PubMed]
7. Schroers, R.; Davis, C.M.; Wagner, H.J.; Chen, S.Y. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther. 2002, 9, 889-897. [PubMed]
8. Bai, X.; Chen, J.D.; Yang, A.G.; Torti, F.; Chen, S.Y. Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene Ther. 1998, 5, 984-994. [CrossRef] [PubMed]
9. Luis Abad, J.; Gonzalez, M.A.; del Real, G.; Mira, E.; Manes, S.; Serrano, F.; Bernad, A. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol. Ther. 2003, 8, 475-484. [CrossRef]
10. Li, L.; Wu, L.P.; Chandrasegaran, S. Functional domains in Fok I restriction endonuclease. Proc. Natl. Acad. Sci. USA 1992, 89, 4275-4279. [CrossRef] [PubMed]
11. Kim, Y.G.; Cha, J.; Chandrasegaran, S. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 1996, 93, 1156-1160. [CrossRef] [PubMed]
12. Tebas, P.; Stein, D.; Tang, W.W.; Frank, I.; Wang, S.Q.; Lee, G.; Spratt, S.K.; Surosky, R.T.; Giedlin, M.A.; Nichol, G., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370, 901-910. [CrossRef] [PubMed]
13. Mussolino, C.; Morbitzer, R.; Lutge, F.; Dannemann, N.; Lahaye, T.; Cathomen, T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011, 39, 9283-9293. [CrossRef] [PubMed]
14. Holkers, M.; Maggio, I.; Liu, J.; Janssen, J.M.; Miselli, F.; Mussolino, C.; Recchia, A.; Cathomen, T.; Goncalves, M.A. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 2013, 41, e63. [CrossRef] [PubMed]
15. Mock, U.; Machowicz, R.; Hauber, I.; Horn, S.; Abramowski, P.; Berdien, B.; Hauber, J.; Fehse, B. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res. 2015, 43, 5560-5571. [CrossRef] [PubMed]
16. Cho, S.W.; Kim, S.; Kim, J.M.; Kim, J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31, 230-232. [CrossRef] [PubMed]
17. Martinez, M.A.; Gutierrez, A.; Armand-Ugon, M.; Blanco, J.; Parera, M.; Gomez, J.; Clotet, B.; Este, J.A. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002, 16, 2385-2390. [CrossRef] [PubMed]
18. Qin, X.F.; An, D.S.; Chen, I.S.; Baltimore, D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 2003,100,183-188. [CrossRef] [PubMed]
19. Boden, D.; Pusch, O.; Lee, F.; Tucker, L.; Ramratnam, B. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 2003, 77, 11531-11535. [CrossRef] [PubMed]
20. Das, A.T.; Brummelkamp, T.R.; Westerhout, E.M.; Vink, M.; Madiredjo, M.; Bernards, R.; Berkhout, B. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 2004, 78, 2601-2605. [CrossRef] [PubMed]
21. Burke, B.P.; Levin, B.R.; Zhang, J.; Sahakyan, A.; Boyer, J.; Carroll, M.V.; Colon, J.C.; Keech, N.; Rezek, V.; Bristol, G., et al. Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector. Mol. Ther. Nucleic Acids 2015, 4, e236. [CrossRef] [PubMed]
22. Wolstein, O.; Boyd, M.; Millington, M.; Impey, H.; Boyer, J.; Howe, A.; Delebecque, F.; Cornetta, K.; Rothe, M.; Baum, C., et al. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol. Ther. Methods Clin. Dev. 2014, 1, e11. [CrossRef] [PubMed]
23. Shimizu, S.; Kamata, M.; Kittipongdaja, P.; Chen, K.N.; Kim, S.; Pang, S.; Boyer, J.; Qin, F.X.; An, D.S.; Chen, I.S. Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet. Vaccines Ther. 2009, 7, e8. [CrossRef] [PubMed]
24. Li, W.; Yu, M.; Bai, L.; Bu, D.; Xu, X. Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells. J. Acquir. Immune Defic. Syndr. 2006, 43, 516-522. [CrossRef] [PubMed]
25. Sarver, N.; Cantin, E.M.; Chang, P.S.; Zaia, J.A.; Ladne, P.A.; Stephens, D.A.; Rossi, J.J.Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990, 247, 1222-1225. [CrossRef] [PubMed]
26. Rossi, J.J. Targeted cleavage: Tuneable cis-cleaving ribozymes. Proc. Natl. Acad. Sci. USA 2007, 104,14881-14882. [CrossRef] [PubMed]
27. Macpherson, J.L.; Boyd, M.P.; Arndt, A.J.; Todd, A.V.; Fanning, G.C.; Ely, J.A.; Elliott, F.; Knop, A.; Raponi, M.; Murray, J., et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J. Gene Med. 2005,7, 552-564. [CrossRef] [PubMed]
28. Sun, L.Q.; Wang, L.; Gerlach, W.L.; Symonds, G. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res. 1995, 23, 2909-2913. [CrossRef] [PubMed]
29. Amado, R.G.; Mitsuyasu, R.T.; Rosenblatt, J.D.; Ngok, F.K.; Bakker, A.; Cole, S.; Chorn, N.; Lin, L.S.; Bristol, G.; Boyd, M.P., et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. 2004,15,251-262.[CrossRef] [PubMed]
30. Mitsuyasu, R.T.; Merigan, T.C.; Carr, A.; Zack, J.A.; Winters, M.A.; Workman, C.; Bloch, M.; Lalezari, J.; Becker, S.; Thornton, L., et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat. Med. 2009, 15, 285-292. [CrossRef] [PubMed]
31. DiGiusto, D.L.; Krishnan, A.; Li, L.; Li, H.; Li, S.; Rao, A.; Mi, S.; Yam, P.; Stinson, S.; Kalos, M., et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010,2, 36ra43. [CrossRef] [PubMed]
32. Yang, A.G.; Bai, X.; Huang, X.F.; Yao, C.; Chen, S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Natl. Acad. Sci. USA 1997, 94, 11567-11572. [CrossRef] [PubMed]
33. Steinberger, P.; Andris-Widhopf, J.; Buhler, B.; Torbett, B.E.; Barbas, C.F., 3rd. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA 2000, 97, 805-810. [CrossRef] [PubMed]
34. Petz, L.D.; Redei, I.; Bryson, Y.; Regan, D.; Kurtzberg, J.; Shpall, E.; Gutman, J.; Querol, S.; Clark, P.; Tonai, R., et al. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol. Blood Marrow Transplant. 2013, 19, 393-397. [CrossRef] [PubMed]
35. Hütter, G.; Nowak, D.; Mossner, M.; Ganepola, S.; Mussig, A.; Allers, K.; Schneider, T.; Hofmann, J.; Kucherer, C.; Blau, O., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360, 692-698. [CrossRef] [PubMed]
36. Yukl, S.A.; Boritz, E.; Busch, M.; Bentsen, C.; Chun, T.W.; Douek, D.; Eisele, E.; Haase, A.; Ho, Y.C.; Hutter, G., et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog. 2013,9, e1003347. [CrossRef][PubMed]
37. Kordelas, L.; Verheyen, J.; Beelen, D.W.; Horn, P.A.; Heinold, A.; Kaiser, R.; Trenschel, R.; Schadendorf, D.; Dittmer, U.; Esser, S. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 2014, 371, 880-882. [CrossRef][PubMed]
38. Hutter, G.; Zaia, J.A. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: The experiences of more than 25 years. Clin. Exp. Immunol. 2011, 163, 284-295. [CrossRef][PubMed]
39. Flepisi, B.T.; Bouic, P.; Sissolak, G.; Rosenkranz, B. Drug-drug interactions in HIV positive cancer patients. Biomed. Pharmacother. 2014, 68, 665-677. [CrossRef][PubMed]
40. Fatkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.I.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B., et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 2008, 359, 1442-1455. [CrossRef] [PubMed]
41. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A.L.; James, I.T.; Jenkins, T.M.; Perros, M.; van der Ryst, E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 2006,80, 4909-4920. [CrossRef] [PubMed]
42. Archer, J.; Braverman, M.S.; Taillon, B.E.; Desany, B.; James, I.; Harrigan, P.R.; Lewis, M.; Robertson, D.L. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009, 23, 1209-1218. [CrossRef] [PubMed]
43. Gray, L.; Churchill, M.J.; Keane, N.; Sterjovski, J.; Ellett, A.M.; Purcell, D.F.; Poumbourios, P.; Kol, C.; Wang, B.; Saksena, N.K., et al. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J. Virol. 2006, 80, 3684-3691. [CrossRef] [PubMed]
44. Henrich, T.J.; Hanhauser, E.; Hu, Z.; Stellbrink, H.J.; Noah, C.; Martin, J.N.; Deeks, S.G.; Kuritzkes, D.R.; Pereyra, F. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Delta32. AIDS 2015, 29, 867-876. [CrossRef] [PubMed]
45. Davey, R.T., Jr.; Bhat, N.; Yoder, C.; Chun, T.W.; Metcalf, J.A.; Dewar, R.; Natarajan, V.; Lempicki, R.A.; Adelsberger, J.W.; Miller, K.D., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 1999, 96, 15109-15114. [CrossRef] [PubMed]
46. Cortes, F.H.; Passaes, C.P.; Bello, G.; Teixeira, S.L.; Vorsatz, C.; Babic, D.; Sharkey, M.; Grinsztejn, B.; Veloso, V.; Stevenson, M., et al. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles. J. Acquir. Immune Defic. Syndr. 2015, 68, 377-385. [CrossRef] [PubMed]
47. Henrich, T.J.; Hu, Z.; Li, J.Z.; Sciaranghella, G.; Busch, M.P.; Keating, S.M.; Gallien, S.; Lin, N.H.; Giguel, F.F.; Lavoie, L., et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 2013, 207,1694-1702. [CrossRef] [PubMed]
48. Henrich, T.J.; Hanhauser, E.; Marty, F.M.; Sirignano, M.N.; Keating, S.; Lee, T.H.; Robles, Y.P.; Davis, B.T.; Li, J.Z.; Heisey, A., et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann. Intern. Med. 2014, 161, 319-327. [CrossRef] [PubMed]
49. Luzuriaga, K.; Gay, H.; Ziemniak, C.; Sanborn, K.B.; Somasundaran, M.; Rainwater-Lovett, K.; Mellors, J.W.; Rosenbloom, D.; Persaud, D. Viremic relapse after HIV-1 remission in a perinatally infected child. N. Engl. J. Med. 2015, 372, 786-788. [CrossRef] [PubMed]
50. Laird, G.M.; Eisele, E.E.; Rabi, S.A.; Lai, J.; Chioma, S.; Blankson, J.N.; Siliciano, J.D.; Siliciano, R.F. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 2013, 9, e1003398. [CrossRef] [PubMed]
51. Zaia, J.A.; Forman, S.J. Transplantation in HIV-infected subjects: Is cure possible? Hematology Am. Soc. Hematol. Educ. Program 2013, 2013, 389-393. [CrossRef] [PubMed]
52. Archin, N.M.; Margolis, D.M. Emerging strategies to deplete the HIV reservoir. Curr. Opin. Infect. Dis. 2014, 27, 29-35. [CrossRef] [PubMed]
53. Elliott, J.H.; Wightman, F.; Solomon, A.; Ghneim, K.; Ahlers, J.; Cameron, M.J.; Smith, M.Z.; Spelman, T.; McMahon, J.; Velayudham, P., et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014, 10, e1004473. [CrossRef] [PubMed]
54. Chirullo, B.; Sgarbanti, R.; Limongi, D.; Shytaj, I.L.; Alvarez, D.; Das, B.; Boe, A.; DaFonseca, S.; Chomont, N.; Liotta, L., et al. A candidate anti-HIV reservoir compound, auranofin, exerts a selective’anti-memory’ effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis. 2013, 4, e944. [CrossRef] [PubMed]
55. Sarkar, I.; Hauber, I.; Hauber, J.; Buchholz, F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007, 316, 1912-1915. [CrossRef] [PubMed]
56. Hu, W.; Kaminski, R.; Yang, F.; Zhang, Y.; Cosentino, L.; Li, F.; Luo, B.; Alvarez-Carbonell, D.; Garcia-Mesa, Y.; Karn, J., et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 2014, 111, 11461-11466. [CrossRef] [PubMed]
57. Hildinger, M.; Dittmar, M.T.; Schult-Dietrich, P.; Fehse, B.; Schnierle, B.S.; Thaler, S.; Stiegler, G.; Welker, R.; von Laer, D. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 2001, 75, 3038-3042. [CrossRef] [PubMed]
58. Schambach, A.; Schiedlmeier, B.; Kuhlcke, K.; Verstegen, M.; Margison, G.P.; Li, Z.; Kamino, K.; Bohne, J.; Alexandrov, A.; Hermann, F.G., et al. Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther. 2006, 13, 1037-1047. [CrossRef] [PubMed]
59. Younan, P.M.; Polacino, P.; Kowalski, J.P.; Peterson, C.W.; Maurice, N.J.; Williams, N.P.; Ho, O.; Trobridge, G.D.; von Laer, D.; Prlic, M., et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 2013, 122, 179-187. [CrossRef][PubMed]
60. Van Lunzen, J.; Glaunsinger, T.; Stahmer, I.; von Baehr, V.; Baum, C.; Schilz, A.; Kuehlcke, K.; Naundorf, S.; Martinius, H.; Hermann, F., et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 2007, 15,1024-1033. [CrossRef] [PubMed]
61. Ledger, S.; Howe, A.; Ong, A.; Boyd, M.; Millington, M.; Savkovic, B.; Murray, J.; Symonds, G. Entry inhibitor gene modifieid T cells show selective survival advantage against HIV infection. Hum. Gene Ther. 2015. Submitted.
62. Li, M.J.; Kim, J.; Li, S.; Zaia, J.; Yee, J.K.; Anderson, J.; Akkina, R.; Rossi, J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12, 900-909. [CrossRef] [PubMed]
63. Anderson, J.; Li, M.J.; Palmer, B.; Remling, L.; Li, S.; Yam, P.; Yee, J.K.; Rossi, J.; Zaia, J.; Akkina, R. Safety and efficacy of a lentiviral vector containing three anti-HIV genes—CCR5 ribozyme, tat-rev siRNA, and TAR decoy—in SCID-hu mouse-derived T cells. Mol. Ther. 2007, 15,1182-1188. [CrossRef] [PubMed]
64. Michienzi, A.; Li, S.; Zaia, J.A.; Rossi, J.J. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. USA 2002, 99, 14047-14052. [CrossRef] [PubMed]
65. Herbert, K.E.; Demosthenous, L.; Wiesner, G.; Link, E.; Westerman, D.A.; Came, N.; Ritchie, D.S.; Harrison, S.; Seymour, J.F.; Prince, H.M. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: A phase I clinical trial. Bone Marrow Transplant. 2014, 49, 1056-1062. [CrossRef] [PubMed]
66. Hsu, W.T.; Jui, H.Y.; Huang, Y.H.; Su, M.Y.; Wu, Y.W.; Tseng, W.Y.; Hsu, M.C.; Chiang, B.L.; Wu, K.K.; Lee, C.M. CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015, 24, 1313-1328. [CrossRef] [PubMed]
67. Didigu, C.A.; Wilen, C.B.; Wang, J.; Duong, J.; Secreto, A.J.; Danet-Desnoyers, G.A.; Riley, J.L.; Gregory, P.D.; June, C.H.; Holmes, M.C., et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood 2014, 123, 61-69. [CrossRef] [PubMed]
68. Reynes, J.; Portales, P.; Segondy, M.; Baillat, V.; Andre, P.; Avinens, O.; Picot, M.C.; Clot, J.; Eliaou, J.F.; Corbeau, P. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001, 15, 1627-1634. [CrossRef] [PubMed]
69. Lin, Y.L.; Mettling, C.; Portales, P.; Reynes, J.; Clot, J.; Corbeau, P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc. Natl. Acad. Sci. USA 2002, 99, 15590-15595. [CrossRef] [PubMed]
70. Mahic, M.; Yaqub, S.; Johansson, C.C.; Tasken, K.; Aandahl, E.M. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 2006, 177, 246-254. [CrossRef] [PubMed]
71. Cutler, C.; Multani, P.; Robbins, D.; Kim, H.T.; Le, T.; Hoggatt, J.; Pelus, L.M.; Desponts, C.; Chen, Y.B.; Rezner, B., et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013, 122, 3074-3081. [CrossRef] [PubMed]